Table 2 Demographic characters, types of cancers, platinum based chemotherapeutic courses and the basal laboratory data of the studied population
From: Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity
Parameters | AKI (+) 35 (100%) | AKI (−) 97(100%) | p-value | Totals 132 (100%) |
|---|---|---|---|---|
Demographic data | ||||
 a. Age (Mean ± SD) | 50.57 ± 13.33 | 49.25 ± 13.29 | 0.615 |  |
  1. <30Y | 4 (11.8%) | 7 (7.1%) |  | 11(8.3%) |
  2. 30–50 | 10 (28.6%) | 38 (39.1%) | 0.68 | 48 (36.4%) |
  3. > 50 | 21 (60.1%) | 52 (53.6%) |  | 73 (55.3%) |
 b. Gender | ||||
  1. Males | 17 (48.6) | 57 (58.8%) | 0.298 | 74 (56%) |
  2. Females | 18 (51.4) | 40 (41.2%) |  | 58 (44%) |
 c. BMI | 23.3 ± 4.1 | 24.3 ± 3.4 | 0.161 | 23.5 ± 4.8 |
Type of cancer | Â | Â | Â | Â |
 a. Gastrointestinal | 19 (54.3%) | 61 (62.9%) |  | 80 (60.6%) |
 b. Respiratory | 6 (17.2) | 21 (21.7%) |  | 27 (20.5%) |
 c. Reproductive | 2 (5.7%) | 6 (6.3%) | 0.5 | 8 (6%) |
 d. Neuroendocrine | 2 (5.7%) | 2 (2.1%) |  | 4 (3%) |
 e. Osteosarcoma | 2 (5.7%) | 2 (2.1%) |  | 4 (3%) |
 f. Others | 4 (11.4%) | 5 (5.25%) |  | 9 (6.8%) |
Received PBD agent: | Â | Â | Â | Â |
 a. Cisplatin (50 mg/m2) | 22 (62.9%) | 49 (50.5%) |  | 71 (53.8%) |
 b. Oxaliplatin (85 mg/m2) | 12 (34.3%) | 41 (42.3%) | 0.45 | 53 (40.2%) |
 c. Carboplatin* | 1 (2.9%) | 4 (4.1%) |  | 5 (3.8%) |
 d. Cispaltin (50 mg/m2) + Carboplatin | 0 | 3 (3.1) |  | 3 (2.3%) |
Basal line laboratory data before PBD: | ||||
 a. Ser. Cr. (mg/dl) | 0.73 ± 0.2 | 0.74 ± 0.3 | 0.85 | 0.73 ± 0.4 |
 b. BUN (mmol/L) | 4.5 ± 1.7 | 4.6 ± 1.5 | 0.74 | 4.5 ± 2 |
 c. eGFR (ml/min) | 102 ± 4 | 103 ± 5.2 | 0.3 | 102 ± 5.7 |
 d. Sodium (mmol/L) | 137.3 ± 5.1 | 136.6 ± 4.6 | 0.45 | 136.9 ± 5.8 |
 e. Potassium (mmol/L) | 3.6 ± 0.7 | 3.7 ± 0.6 | 0.42 | 3.6 ± 0.9 |
 f. Calcium (mg/dl) | 9.66 ± 1.05 | 9.50 ± 0.50 | 0.412 | 9.5 ± 1.1 |
KIM-1 | Â | Â | Â | Â |
(0 day) | 1.04 ± 0.2 (0.84–1.24) | 1.2 ± 0.21 (0.99-1.41) | 0.39 |  |